Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

NCT04683250 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04683250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04683250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 16, 2020
Completion date
March 31, 2031
Enrollment
244 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

ret-altered non small cell lung cancer, ret-altered solid tumors